FRANCISCO GOMEZ VEIGA

Prof. Dr. FRANCISCO GOMEZ VEIGA

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2012 in BJU International
Verified
Journal Article
Closed access
PDF file
FVFRANCISCO GOMEZ VEIGA
FRANCISCO GOMEZ VEIGA
AMAlfonso Mariño
Alfonso Mariño
LALuis Alvarez
Luis Alvarez
IRIgnacio Rodriguez
Ignacio Rodriguez
CFCarlos Fernandez
Carlos Fernandez
ACArturo Candal
Arturo Candal

16 October 2019 in BMC Urology
Verified
Journal Article
Open access
PDF file
AAA. Rodríguez Antolín
A. Rodríguez Antolín
LML. Martínez-Piñeiro
L. Martínez-Piñeiro
MRM. E. Jiménez Romero
M. E. Jiménez Romero
JRJ. B. García Ramos
J. B. García Ramos
DBD. López Bellido
D. López Bellido
FVFRANCISCO GOMEZ VEIGA
FRANCISCO GOMEZ VEIGA
Background: Fatigue is one of the most prevalent symptoms among cancer patients. Specifically, in metastatic castration-resistant prostate cancer (mCRPC) patients, fatigue is the most common adverse event associated with current treatments. The purpose of this study is to describe the prevalence of fatigue and its impact on quality of life (QoL) in patients with CRPC in routine clinical practice. Methods: This was a cross-sectional, multicentre study. Male chemo-naïve adults with high-risk non-metastatic (M0) CRPC and metastatic (M1) CRPC (mCRPC) were eligible. Fatigue was measured using the Brief Fatigue Inventory (BFI) and QoL was assessed using the Functional Assessment of Cancer Therapy questionnaire for patients with prostate cancer (FACT-P) and the FACT-General (FACT-G) questionnaire. Data were analysed using Mann-Whitney or Kruskal-Wallis tests (non-parametric distribution), a T-test or an ANOVA (parametric distribution) and the Fisher or chi-squared tests (categorical variables). Results: A total of 235 eligible patients were included in the study (74 [31.5%] with M0; and 161 [68.5%] with M1). Fatigue was present in 74%, with 38.5% of patients reporting moderate-to-severe fatigue. Mean FACT-G and FACT-P overall scores were 77.6 ± 16.3 and 108.7 ± 21.4, respectively, with no differences between the CRPC M0 and CRPC M1 subgroups. Fatigue intensity was associated with decreased FACT-G/P scores, with no differences between groups. Among 151 mCRPC patients with available treatment data, those treated with abiraterone-prednisone ≥3 months showed a significant reduction in fatigue intensity (p = 0.043) and interference (p = 0.04) compared to those on traditional hormone therapy (HT). Patients on abiraterone-prednisone ≥3 months showed significantly better FACT-G/P scores than patients on HT (p = 0.046 and 0.018, respectively). Conclusion: Our data show a high prevalence and intensity of fatigue and its impact on QoL in chemo-naïve CRPC patients. There is an association between greater fatigue and less QoL, irrespective of the presence or absence of metastasis. Chemo-naïve mCRPC patients receiving more than 3 months of abiraterone acetate plus prednisone showed an improvement of fatigue and QoL when compared to those on traditional HT. Trial registration: Not applicable since it is not an interventional study.

9 December 2023 in European Urology Oncology
Verified
Journal Article
Open access
FVFRANCISCO GOMEZ VEIGA
FRANCISCO GOMEZ VEIGA
RSRussell Z. Szmulewitz
Russell Z. Szmulewitz
JHJeffrey Holzbeierlein
Jeffrey Holzbeierlein
AAArun A. Azad
Arun A. Azad
TITaro Iguchi
Taro Iguchi
AAAndrew J. Armstrong
Andrew J. Armstrong
In ARCHES, treatment intensification of androgen deprivation therapy (ADT) with enzalutamide versus placebo improved clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC). Understanding the benefits and tolerability of enzalutamide for men aged ≥75 yr may inform disease management. To determine whether age is associated with clinical outcomes in mHSPC. A post hoc analysis of the multinational, double-blind, randomized, placebo-controlled, phase 3 ARCHES trial in 1150 men with mHSPC (median follow-up [mo]: <75 yr, 44.6; ≥75 yr, 44.3) was performed. Randomization 1:1 to enzalutamide (160 mg/d) plus ADT or placebo plus ADT; stratification by disease volume and prior docetaxel use. Overall survival (OS), radiographic progression-free survival (rPFS), safety, and other secondary endpoints were compared between age groups (<75 and ≥75 yr) and treatment arms (Cox proportional hazard models). Men aged <75 versus ≥75 yr had longer OS (enzalutamide plus ADT: hazard ratio [HR] 0.66; 95% confidence interval [CI] 0.47-0.91; p = 0.02; placebo plus ADT: HR 0.81; 95% CI 0.60-1.09; p = 0.13) and rPFS (enzalutamide plus ADT: HR 0.78; 95% CI 0.58-1.04; p = 0.12; placebo plus ADT: HR 0.98; 95% CI 0.74-1.30; p = 0.007). Enzalutamide improved OS (<75 yr: HR 0.61; 95% CI 0.47-0.79; ≥75 yr: HR 0.76; 95% CI 0.54-1.09) and secondary efficacy endpoints without evidence of statistical heterogeneity, and was generally well tolerated in both age groups, with minimal quality-of-life impact. Older versus younger patients experienced more frequent dose interruptions (20.2% vs 10.9%) and treatment-emergent adverse events (95.2% vs 89.1%). Post hoc examination and small sample size preclude definitive conclusions. Enzalutamide plus ADT improved efficacy outcomes and was generally well tolerated despite shorter treatment exposure in older patients, indicating enzalutamide's utility in patients with mHSPC aged <75 and ≥75 yr. Enzalutamide is a drug approved to treat men with prostate cancer. In this report, we compared patients aged <75 and ≥75 yr treated with enzalutamide plus androgen deprivation therapy to determine whether age affected how long they lived without the cancer spreading to other parts of their body. We found that, although younger patients had more favorable survival outcomes, enzalutamide was associated with longer survival and reduced disease spread in both age groups.

1 July 2017 in Actas Urológicas Españolas
Verified
Journal Article
Closed access
FVFRANCISCO GOMEZ VEIGA
FRANCISCO GOMEZ VEIGA
ARA. Rodríguez-Antolín
A. Rodríguez-Antolín
BLBernardino Miñana López
Bernardino Miñana López
CHC. Hernández
C. Hernández
JSJ.F. Suárez
J.F. Suárez
JCJ.M. Cózar
J.M. Cózar

1 May 2013 in Actas Urológicas Españolas
Verified
Journal Article
Closed access
FVFRANCISCO GOMEZ VEIGA
FRANCISCO GOMEZ VEIGA
JDJose Ponce Díaz-Reixa
Jose Ponce Díaz-Reixa
SMS. Martinez-Breijo
S. Martinez-Breijo
JPJ. Planas
J. Planas
JMJuan Morote
Juan Morote

1 June 2011 in Actas Urológicas Españolas
Verified
Journal Article
Closed access
FVFRANCISCO GOMEZ VEIGA
FRANCISCO GOMEZ VEIGA
AAAntonio Alcaraz
Antonio Alcaraz
JBJ. Burgos-Revilla
J. Burgos-Revilla
JCJ.M. Cózar-Olmo
J.M. Cózar-Olmo